Introduction: Management of human papillomavirus (HPV)-positive/cytology-negative patients has represented a special challenge ever since the introduction in 2003 of routine cytology and HPV cotesting of women 30 years and older. Since the U.S. Food and Drug Administration's approval in 2009 of an HPV 16/18 genotyping test, guidelines have included an HPV 16/18 genotyping triage option for identifying high-risk HPV-positive/cytology-negative patients who would benefit from immediate colposcopic referral.
Materials And Methods: A retrospective database search was conducted to identify patients with HPV-positive/cytology-negative results between May 1, 2010 and June 30, 2013 in an academic women's hospital practice in which clinical staff consented to routine HPV 16/18 genotyping triage testing of women 30 years and older with HPV-positive/cytology-negative results.
Results: Of 824 cytology-negative/HPV-positive cases with valid HPV 16/18 genotyping results, positive results were obtained in 101 (12.3%). HPV 16 was detected most frequently (9.1%), followed by HPV 18 (2.4%) and both 16 and 18 (0.7%). Histopathologic follow-up results were documented over an average of 3.5 months (range 0.5 to 22.5) in 51 patients with HPV-positive/cytology-negative/HPV 16/18-positive results; cervical intraepithelial neoplasia 2/3 biopsy diagnoses were reported in 4 of 51 (7.8%). Previously we reported cervical intraepithelial neoplasia 2+ diagnoses in 2.4% of 849 high-risk HPV-positive/cytology-negative patients followed for almost 2 years without HPV 16/18 genotype testing.
Conclusions: These initial routine clinical practice findings are consistent with data from both long-term research studies and recent shorter term clinical trials indicating enhanced risk stratification of HPV-positive/cytology negative patients with HPV 16/18 genotype testing. This is the first report of the application of this option in a routine clinical practice setting.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jasc.2015.03.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
GX-188E DNA vaccine plus pembrolizumab in HPV 16- and/or 18-positive recurrent or advance cervical cancer: a phase 2 trial.
EClinicalMedicine
August 2024
Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Background: In an interim analysis of this phase 2 trial, adding the GX-188E vaccine to pembrolizumab resulted in manageable toxicity with antitumor activities in patients with recurrent or advanced cervical cancer. Here, we report the final safety and efficacy results after a long-term follow-up at the study's completion.
Methods: This open-label, single-arm, phase II trial was conducted in nine hospitals in South Korea (ClinicalTrials.
Delivering Guideline-Concordant Care for Patients With High-Risk HPV and Normal Cytologic Findings.
JAMA Netw Open
January 2025
Division of General Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston.
Importance: As US health care systems shift to human papillomavirus (HPV)-based cervical cancer screening, more patients are receiving positive high-risk non-16/18 genotype HPV results and negative for intraepithelial lesion or malignancy (NILM) cytological findings. Risk-based management guidelines recommend 2 consecutive negative annual results to return to routine screening.
Objective: To quantify patterns of surveillance testing and associated outcomes for patients after an HPV-positive results and NILM cytologic findings.
Oncoproteins E6/E7 of the human papillomavirus types 16 & 18 synergize in modulating oncogenes and tumor suppressor proteins in colorectal cancer.
Expert Rev Proteomics
January 2025
College of Medicine, QU Health, Qatar University, Doha, Qatar.
Objective: Our study presents a novel analysis of the oncogenes and tumor suppressor proteins directly modulated by E6/E7 of high-risk HPV types 16 and 18, in colorectal cancer (CRC).
Methods: HCT 116 (KRAS mutant) & HT-29 (TP53 mutant) cell models of CRC were transduced with E6/E7 of HPV16 and HPV18, individually and in combination. Further, we utilized a liquid chromatography mass spectrometry (LC-MS/MS) approach to analyze and compare the proteomes of both CRC cell models.
A Preclinical Immunogenicity Study of the Recombinant Human Papillomavirus Nine-Valent Virus-like Particle Vaccine.
Vaccines (Basel)
November 2024
Shanghai Zerun Biotech Co., Ltd., Building 9, 1690 Zhangheng Road, Pudong, Shanghai 201203, China.
Background: Cervical cancer is associated with persistent infection of high-risk human papillomaviruses (HPVs). Prophylactic HPV vaccines have been recommended and have significant efficacy in preventing cervical cancer. Multivalent HPV vaccines have a better preventative effect on HPV-related diseases.
View Article and Find Full Text PDFImmunogenicity and safety of the fourth dose of quadrivalent human papillomavirus (HPV) vaccine in immunosuppressed women who did not seroconvert after three doses.
Front Cell Infect Microbiol
January 2025
Departamento de Infectologia e Medicina Tropical, Faculdade de Medicina da Universidade de Sao Paulo (FMUSP), Sao Paulo, Brazil.
Introduction: Immunocompromised persons have high risk of persistent human papillomavirus (HPV) infection and HPV-related diseases, and lower immune response to vaccines. This study evaluated the immunogenicity and safety of administering a fourth dose of quadrivalent (4v)HPV vaccine in immunosuppressed women who did not seroconvert after three doses.
Methods: An open-label, not-controlled trial included immunosuppressed women (solid organ transplant patients and women receiving treatment for SLE) who did not seroconvert to at least one of the four HPV vaccine types after three 4vHPV vaccine doses.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!